Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMpac Group Plc Regulatory News (MPAC)

Share Price Information for Mpac Group Plc (MPAC)

Share Price is delayed by 15 minutes
Get Live Data
262.50    -10.00 (-3.67%)
Bid:
260.00
Ask:
265.00
Spread: 5.00 (1.923%)
Market Cap: £78.94m
MPAC Live PriceLast checked at - London Stock Exchange

Intraday Mpac Group Plc Share Chart

Full Year Trading update

16 Jan 2025 07:00

RNS Number : 4994T
Mpac Group PLC
16 January 2025
 

16 January 2025

AIM: MPAC

 

Mpac Group plc

(''Mpac'', "Company" or "Group")

 

Full Year Trading update

 

FY24 trading performance in line with market expectations, a healthy opening order book for 2025 and good initial progress made on integrating H2 24 acquisitions

 

 

Mpac Group plc, a global leader in high-speed packaging and automation solutions, today announces a trading update (unaudited) for the year ended 31 December 2024 ("FY24").

 

The Board is pleased with the Group's FY24 performance and expects that it will report underlying profit before tax in line with market expectations of £10.5m (FY23: £7.1m). As anticipated, profit before tax in H2 24 was substantially above H1 24, aided by improving project margins and operational efficiencies.

 

The Group successfully executed the acquisitions of BCA Automation and CSi Palletising in H2 24 (the "Acquisitions"). The Acquisitions have continued to perform in line with the Board's expectations. The integration is progressing well and according to plan.

 

After the completion of the Acquisitions, the Group closes FY24 with net debt of £37.0m (FY23: net cash £2.1m) and a reduction in working capital to £7.0m (FY23: £13.2m), which includes circa £8.0m of invoiced receivables, due in 2024, most of which has been received in early January 2025. The Group remains on track to bring net debt down to less than 1 times EBITDA by the end of 2025.

 

Quote activity and the prospect pipeline within the growth sectors in which Mpac operates of Healthcare and Food and Beverage continues to be strong and following the Acquisitions, the Group ended FY24 with an increased value of the closing order book at c.£111.0m (FY23: £72.5m) providing good coverage over 2025 forecast revenue. 

 

With an increasingly diverse prospect pipeline and order book and good quote activity, as well as a stronger offering through combined product lines from our existing and acquired businesses, the Group is well placed to deliver on market expectations for the current financial year and beyond. The Board remains confident that the Group will continue progressing its long-term growth strategy.

 

Adam Holland, Chief Executive, commented:

 

We are pleased with full year 2024 financial performance, which is in line with market expectations. 2024 has proved to be a transformational year for the Group, with the acquisitions of CSi, BCA and Siga Vision providing the platform for a step change in scale and profitability, accelerating our progress towards our strategic objectives. The acquisitions materially diversify the Group's portfolio enabling the Group to provide a fuller line offering, as well as access to new customer relationships providing a platform for continued robust organic growth.

 

We would like to thank shareholders for their support of the acquisition of CSi and their ongoing support as we head into 2025. We anticipate reporting for 2024 record levels of revenue, with underlying profit before tax breaking through the £10m mark for the first time. We start 2025 with a larger and more diverse order book from our resilient end markets providing a high level of coverage over forecast revenue, supporting delivery of our expectations for further growth in the year ahead.''

 

The Group's full year results for the year ended 31 December 2024 are expected to be announced in the week commencing 28 April 2025, allowing for the additional time required to complete the first audit of the enlarged Group following the recent significant acquisitions.

 

 

For further information, please contact:

Mpac Group plc

Adam Holland, Chief Executive

Will Wilkins, Chief Financial Officer

Tel: +44(0)24 7642 1100

Shore Capital (Nominated Adviser & Broker)

Advisory

Patrick Castle

Sophie Collins

Broking

Henry Willcocks

 

 

Tel: +44(0)20 7408 4050

 

Panmure Liberum (Joint Broker)

Edward Mansfield

Will King

Anake Singh

 

Hudson Sandler (Financial PR)

Nick Lyon

Nick Moore

Francesca Rosser

Tel: +44 (0) 20 3100 2000

 

 

 

 

Tel: +44 (0) 20 7796 4133

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGPUCCGUPAGMA
Date   Source Headline
15th Aug 20247:00 amRNSAcquisition of SIGA Vision Ltd
10th Jul 20247:00 amRNSTrading Update and Notice of Results
22nd May 202412:36 pmRNSFirst FREYR Battery Unit Cell Production Trial
15th May 20243:10 pmRNSResult of AGM
15th May 20247:00 amRNSAGM Statement
26th Apr 20247:35 amRNSSiSTEM pilot battery assembly line
17th Apr 20247:00 amRNSLaunch of ESG Report
9th Apr 20241:12 pmRNSGrant of Options
8th Apr 20242:15 pmRNSNotice of AGM
19th Mar 20247:00 amRNSFull Year Results
21st Feb 20247:00 amRNSEquity Development Investor Presentation
16th Feb 20247:00 amRNSNotice of Results
11th Jan 20247:00 amRNSFull Year Trading Update
4th Dec 202311:51 amRNSDirector/PDMR Shareholding
27th Nov 202311:36 amRNSDirector/PDMR Dealing
18th Oct 20232:42 pmRNSHolding(s) in Company
12th Oct 20237:00 amRNSAppointment of Joint Broker
22nd Sep 202311:19 amRNSHolding(s) in Company
7th Sep 20237:00 amRNSHalf Year Results
17th Aug 20237:00 amRNSEquity Development Investor Webinar
11th Jul 20237:00 amRNSTrading Update and Notice of Results
30th May 202310:52 amRNSDirector/PDMR Shareholding
18th May 202311:17 amRNSResult of Annual General Meeting
17th May 20237:00 amRNSAGM Statement
2nd May 20234:37 pmRNSDirector/PDMR Transaction
6th Apr 20235:30 pmRNSAvailability of Annual Report and Notice of AGM
27th Mar 202310:53 amRNSDirector/PDMR Dealing
22nd Mar 20237:01 amRNSCEO succession
22nd Mar 20237:00 amRNSFull Year Results
20th Feb 20237:00 amRNSEquity Development Investor Presentation
17th Feb 20237:00 amRNSNotice of Results
16th Jan 20237:00 amRNSFull Year Trading Update
24th Oct 20222:20 pmRNSDirectorate Appointment
14th Oct 202210:58 amRNSReplacement - PDMR Dealing & Total Voting Rights
12th Oct 20224:59 pmRNSDirector/PDMR Dealing & Total Voting Rights
15th Sep 202212:50 pmRNSMpac signs FREYR framework agreement
13th Sep 20227:00 amRNSEquity Development Investor Presentation
9th Sep 20222:16 pmRNSDirector/PDMR Transaction
8th Sep 20227:00 amRNSHalf Year Result
11th Jul 20227:00 amRNSTrading Update and Notice of Results
24th Jun 20222:54 pmRNSAppointment of new auditor
10th Jun 20224:10 pmRNSGrant of Options
27th May 20222:56 pmRNSDirectors/PDMRs Dealing
25th May 20224:13 pmRNSHolding(s) in Company
19th May 20223:57 pmRNSEBT Subscription & Total Voting Rights
13th May 20224:25 pmRNSDirectors/PDMRs Dealing - Replacement
12th May 20224:46 pmRNSDirectors/PDMRs Dealing
4th May 20224:16 pmRNSResult of AGM
4th May 20227:00 amRNSAGM Statement
17th Mar 20227:00 amRNSFull Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.